Smith+Nephew released its Q2 and first half 2026 results
Smith+Nephew reported Q2 revenue of $1,597 million, up 1.6% underlying, and H1 trading profit of $566 million, up 8.1%. Full-year revenue growth guidance was lowered from 6% to 4%.
See the latest news and media coverage for Smith+Nephew. We track all announcements, press releases, and industry mentions in real time, all in one place.
Medical technology company focused on tissue repair, regeneration and replacement
smith-nephew.comLast updated
In short: Smith+Nephew reported a profit jump in 2025 but lowered its 2026 revenue guidance due to underperformance in its U.S. orthopaedic unit.
Smith+Nephew reported Q2 revenue of $1,597 million, up 1.6% underlying, and H1 trading profit of $566 million, up 8.1%. Full-year revenue growth guidance was lowered from 6% to 4%.
The strategy includes a new delivery model and partnerships to help ambulatory surgery centers improve performance.
A PDMR transaction has been disclosed in compliance with regulations.
It shows growth across all units and regions, innovation-driven growth, unchanged guidance, and $500 million share buyback.
Smith & Nephew PLC - Hertfordshire, England-based medical technology, focused on repair, regeneration and replacement of soft and hard tissue - Prices tender offer for...
First came “9 to 5.”� Then came the business empire, rooted in the place Dolly Parton called home.
Detailed price information for Smith & Nephew Snats ADR (SNN-N) from The Globe and Mail including charting and trades.
Smith & Nephew stock has moved on governance news after its CFO departure, with investors weighing the latest half-year 2026 ...
Track Smith+Nephew and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Smith+Nephew and other trending companies.